Abstract:Background: Oritavancin is a new generation of semi-synthetic glycopeptide antibiotics against Gram-positive bacteria, which served as the first and only antibiotic with a single-dose therapeutic regimen to treat ABSSSI. A naturally occurring glycopeptide A82846B is the direct precursor of oritavancin. However, its application has been hampered by low yields and homologous impurities. This study established a multi-step combinatorial strategy to rationally construct a high-quality and high-efficiency biosynthesis system for A82846B and systematically optimize its fermentation process to break through the bottleneck of microbial fermentation production. Results: Firstly, based on the genome sequencing and analysis, we deleted putative competitive pathways and constructed a better A82846B-producing strain with a cleaner metabolic background, increasing A82846B production from 92 to 174 mg/L. Subsequently, the PhiC31 integrase system was introduced based on the CRISPR-Cas12a system. Then, the fermentation level of A82846B was improved to 226 mg/L by over-expressing the pathway-specific regulator StrR via the constructed PhiC31 system. Furthermore, overexpressing glycosyl-synthesis gene evaE enhanced the production to 332 mg/L due to the great conversion of the intermediate to target product. Finally, the scale-up production of A82846B reached 725 mg/L in a 15 L fermenter under fermentation optimization, which is the highest reported yield of A82846B without the generation of homologous impurities. Conclusion: Under approaches including blocking competitive pathways, inserting site-specific recombination system, overexpressing regulator, overexpressing glycosyl-synthesis gene and optimizing fermentation process, a multi-step combinatorial strategy for the high-level production of A82846B was developed, constructing a high-producing strain AO-6. The combinatorial strategies employed here can be widely applied to improve the fermentation level of other microbial secondary metabolites, providing a reference for constructing an efficient microbial cell factory for high-value natural products.

Production of Plant Sesquiterpene Lactone Parthenolide in the Yeast Cell Factory

Cell-Free Production of Pentacyclic Triterpenoid Compound Betulinic Acid from Betulin by the Engineered Saccharomyces cerevisiae.

De novo production of the plant-derived alkaloid strictosidine in yeast

Establishing cell suitability for high-level production of licorice triterpenoids in yeast

Engineering yeast subcellular compartments for increased production of the lipophilic natural products ginsenosides

Reassembly of the Biosynthetic Gene Cluster Enables High Epothilone Yield in Engineered Schlegelella Brevitalea.

Combination of microbial and chemical synthesis for the sustainable production of β‐elemene, a promising plant‐extracted anticancer compound

Development of a Pichia pastoris cell factory for efficient production of germacrene A: a precursor of β-elemene

De Novo Biosynthesis of Vindoline and Catharanthine in Saccharomyces cerevisiae

Optimization of Tabersonine Methoxylation to Increase Vindoline Precursor Synthesis in Yeast Cell Factories

Back to the plant: overcoming roadblocks to the microbial production of pharmaceutically important plant natural products

Biosynthesis of catharanthine in engineered Pichia pastoris

Boosting the biosynthesis of betulinic acid and related triterpenoids in Yarrowia lipolytica via multimodular metabolic engineering

High-level sustainable production of complex phenylethanoid glycosides from glucose through engineered yeast cell factories

Complete biosynthesis of noscapine and halogenated alkaloids in yeast

Efficient production of an antitumor precursor actinocin and other medicinal molecules from kynurenine pathway in Escherichia coli

Rational construction of a high-quality and high-efficiency biosynthetic system and fermentation optimization for A82846B based on combinatorial strategies in Amycolatopsis orientalis

De novo production of bioactive sesterterpenoid ophiobolins in Saccharomyces cerevisiae cell factories

Organelle Engineering in Yeast: Enhanced Production of Protopanaxadiol through Manipulation of Peroxisome Proliferation in Saccharomyces cerevisiae

Synthesizing ginsenoside Rh2 in Saccharomyces cerevisiae cell factory at high-efficiency

Enhanced bioproduction of anticancer precursor vindoline by yeast cell factories